Cargando…
Ventilator-associated pneumonia: monotherapy is optimal if chosen wisely
Traditionally, ventilator-associated pneumonia (VAP) has been treated either with double drug therapy or with monotherapy. Double drug therapy has been used to increase spectrum, for possible synergy, and to decrease the emergence of resistance. VAP therapy should be directed primarily against Pseud...
Autor principal: | Cunha, Burke A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550899/ https://www.ncbi.nlm.nih.gov/pubmed/16677419 http://dx.doi.org/10.1186/cc4908 |
Ejemplares similares
-
Biological markers and diagnosis of ventilator-associated pneumonia
por: Fagon, Jean-Yves
Publicado: (2011) -
Cost effectiveness in treating ventilator-associated pneumonia
por: Niederman, Michael S
Publicado: (2001) -
Advancing the science of ventilator-associated pneumonia surveillance
por: Klompas, Michael
Publicado: (2012) -
COVID-19: An Alert to Ventilator-Associated Bacterial Pneumonia
por: Póvoa, Helvécio Cardoso Corrêa, et al.
Publicado: (2020) -
The Chosen Few: Only a Subset of Memory B Cells Responds to Secondary Dengue Virus Infections
por: Bhattacharya, Deepta, et al.
Publicado: (2016)